Research programme: intranasal HIV vaccine - NanoBio

Drug Profile

Research programme: intranasal HIV vaccine - NanoBio

Alternative Names: nanoemulsion-based HIV vaccine - NanoBio

Latest Information Update: 28 Jul 2016

Price : $50

At a glance

  • Originator NanoBio Corporation
  • Developer Duke Human Vaccine Institute; NanoBio Corporation; National Institutes of Health (USA)
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 28 Jul 2016 Preclinical development is ongoing for HIV infections in USA (NanoBio Corporation pipeline, July 2016)
  • 29 Oct 2013 NanoBio Corporation receives contract from National Institute of Allergy and Infectious Diseases for intranasal HIV vaccine development in prevention of HIV infections
  • 29 Oct 2013 Preclinical trials in HIV infections (prevention) in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top